Amlodipine/benazepril - Novartis

Drug Profile

Amlodipine/benazepril - Novartis

Alternative Names: Amlodipine besylate/benazepril hydrochloride; Lotrel

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Novartis Pharmaceuticals Corporation
  • Class Antihypertensives; Benzazepines; Dihydropyridines; Ischaemic heart disorder therapies
  • Mechanism of Action ACE inhibitors; Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 16 Jun 2009 Efficacy data from the phase III ACCOMPLISH trial in Hypertension presented at the 19th European Meeting on Hypertension (ESH-2009)
  • 05 Dec 2008 Final efficacy and adverse events data from the phase III ACCOMPLISH trial in Hypertension released by Novartis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top